Joan Walker to Papillomaviridae
This is a "connection" page, showing publications Joan Walker has written about Papillomaviridae.
Connection Strength
1.305
-
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):113-20.
Score: 0.308
-
Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis. 2015 Nov 25; 15:544.
Score: 0.124
-
Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic. J Clin Microbiol. 2014 Jan; 52(1):187-92.
Score: 0.108
-
Reproducibility of linear array for human papillomavirus genotyping. J Clin Microbiol. 2013 Feb; 51(2):625-8.
Score: 0.101
-
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer Causes Control. 2012 Dec; 23(12):2013-21.
Score: 0.100
-
Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. J Clin Microbiol. 2012 May; 50(5):1564-70.
Score: 0.096
-
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer. 2009 Nov 15; 125(10):2434-40.
Score: 0.082
-
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006 Aug; 195(2):341-8.
Score: 0.065
-
Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 20; 117(6):1007-12.
Score: 0.062
-
High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer. J Natl Compr Canc Netw. 2004 Nov; 2(6):589-96.
Score: 0.058
-
Management of atypical and low-grade cervical cytology. Cancer J. 2003 Sep-Oct; 9(5):377-81.
Score: 0.053
-
Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathol. 2018 11; 126(11):950-958.
Score: 0.038
-
Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015 Jan 01; 33(1):83-9.
Score: 0.029
-
Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. J Clin Virol. 2014 Aug; 60(4):414-7.
Score: 0.028
-
Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. Int J Cancer. 2014 Jan 15; 134(2):411-25.
Score: 0.026
-
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer. 2003 Nov 01; 98(9 Suppl):2044-51.
Score: 0.013
-
Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol. 2002 Jan; 22(1):23-7.
Score: 0.012